The European Medicines Agency has approved Pelgraz (pegfilgrastim) and in some countries it could be in the hands of healthcare professionals this week, making it the first biosimilar of Amgen’s (Nasdaq: AMGN) Neulasta to reach patients in Europe.
Pelgraz is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia for adult patients undergoing cytotoxic chemotherapy. Its biosimilarity with Neulasta has been backed up by Phase III data.
The company behind Pelgraz is Accord Healthcare, a UK-based subsidiary of Indian biopharma company Intas Pharmaceuticals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze